コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 eta and interleukin-6) and chemokine (MCP-1; monocyte chemoattractant protein).
2 creases in interleukin-6 (21%; P < 0.02) and monocyte chemoattractant protein 1 (14% decrease at 4 wk
4 ll alpha chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein 1 (CCL2) were measured
5 CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinic
6 ssion of the fibrocyte recruiting chemokines monocyte chemoattractant protein 1 (MCP-1) and CXCL12, a
7 ed, there was a significant decrease in CCL2/monocyte chemoattractant protein 1 (MCP-1) and inflammat
8 stability of tumor necrosis factor alpha and monocyte chemoattractant protein 1 (MCP-1) but strongly
9 low-density lipoprotein (ox-LDL)-stimulated monocyte chemoattractant protein 1 (MCP-1) from macropha
10 d various levels of interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t
11 lammatory cytokines interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t
12 ssion of the inflammatory mediators CD36 and monocyte chemoattractant protein 1 (MCP-1) in the brain
18 ar adhesion molecule 1 (ICAM-1), E-selectin, monocyte chemoattractant protein 1 (MCP-1), and interleu
19 ndent secretion of CRS biomarkers, including monocyte chemoattractant protein 1 (MCP-1), interleukin
21 ter infection (day 2), interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-1), macrophage i
22 anulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant protein 1 (MCP-1), macrophage i
23 s of IFN-gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage i
24 IL-12, and IL-18; chemokines, such as IL-8, monocyte chemoattractant protein 1 (MCP-1), RANTES, and
25 rogenase, and inflammatory mediators such as monocyte chemoattractant protein 1 (MCP-1), TNF-alpha, a
30 , we show that T. cruzi strongly upregulates monocyte chemoattractant protein 1 (MCP-1)/CCL2 and frac
32 , S1P stimulated secretion of the chemokine, monocyte chemoattractant protein 1 (MCP-1/CCL2), from th
33 rleukin-6 (Il-6), interleukin-1beta (Il-1b), monocyte chemoattractant protein 1 (Mcp1), and fibrosis-
34 , TNF-alpha (P = .006), IL-1beta (P = .022), monocyte chemoattractant protein 1 (P = .028), RANTES (P
35 ta, IL-23, interferon (IFN)-beta, IFN-gamma, monocyte chemoattractant protein 1 [MCP-1; chemokine (C-
36 mor necrosis factor alpha (TNF-alpha), CCL2 (monocyte chemoattractant protein 1 [MCP-1]), and CCL5 (R
38 ines (interleukin 6 [IL-6], IL-8, IL-1alpha, monocyte chemoattractant protein 1 [MCP-1], and colony-s
39 atory cytokines (interleukin-6 [IL-6], IL-8, monocyte chemoattractant protein 1 [MCP-1], and IL-1beta
41 diponectin and leptin while reducing that of monocyte chemoattractant protein 1 and interleukin-8 by
42 eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-deri
43 alveolar epithelial cells produced excessive monocyte chemoattractant protein 1 and reactive oxygen s
46 of tumor necrosis factor, interleukin-6, and monocyte chemoattractant protein 1 by spleen cells was a
47 12p40, interferon-inducible protein 10, and monocyte chemoattractant protein 1 concentrations, where
48 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in lumbar spinal cord
49 on of interleukin 1beta, interleukin 10, and monocyte chemoattractant protein 1 in response to ZIKV,
50 ction was strongly correlated with increased monocyte chemoattractant protein 1 levels (r = 0.396, P
51 educed IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without af
52 ), monokine induced by interferon-gamma, and monocyte chemoattractant protein 1 were quantified as me
53 ion of chemokine (C-C motif) ligand (CCL) 2 (monocyte chemoattractant protein 1) and CCL3 (macrophage
54 ellular protease plasmin cleaves mouse MCP1 (monocyte chemoattractant protein 1) at lysine 104, relea
55 of THP-1 monocytes to migrate toward MCP-1 (monocyte chemoattractant protein 1) depended upon Par3 a
56 necrosis factor alpha, interleukin-6, CCL2 (monocyte chemoattractant protein 1), and CCL5 (RANTES).
57 F-beta, connective tissue growth factor, and monocyte chemoattractant protein 1), and epithelial-to-m
58 rleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mes
59 emokine, C-C motif chemokine ligand 2 (CCL2; monocyte chemoattractant protein 1), termed mNOX-E36, in
60 induced inflammation (tumor necrosis factor, monocyte chemoattractant protein 1, and chemokine [C-X-C
61 s of myeloperoxidase, tumor necrosis factor, monocyte chemoattractant protein 1, and gamma interferon
62 eukin 1beta (IL-1beta), IL-6, CXCL1/KC, CCL2/monocyte chemoattractant protein 1, and granulocyte colo
63 terleukin-6, keratinocyte-derived chemokine, monocyte chemoattractant protein 1, and interleukin-10),
64 e, with extremely high mRNA levels for IL-8, monocyte chemoattractant protein 1, and macrophage infla
65 asminogen activator receptor, interleukin-6, monocyte chemoattractant protein 1, and matrix metallopr
66 nterferon gamma-inducible protein of 10 kDa, monocyte chemoattractant protein 1, growth-related oncog
67 accumulation, apoptosis, necrotic cores, and monocyte chemoattractant protein 1, interleukin 1beta, i
68 ing factor were significantly reduced, while monocyte chemoattractant protein 1, macrophage inflammat
69 erestingly, higher levels of interleukin 22, monocyte chemoattractant protein 1, TNF-alpha, and IP-10
70 sion of proinflammatory cytokines (including monocyte chemoattractant protein 1, tumor necrosis facto
71 ential of mouse melanoma cells in HDAC3- and monocyte chemoattractant protein 1-(MCP1)-dependent mann
76 terferon [IFN-gamma], and IL-6), chemokines (monocyte chemoattractant protein 1/CCL-2, macrophage inf
77 of histamine, cytokines, and the chemokines monocyte chemoattractant protein 1/CCL2, macrophage infl
78 biomarkers (glial fibrillary acidic protein, monocyte chemoattractant protein 1/chemokine (C-C motif)
79 glial fibrillary acidic protein (p = 0.002), monocyte chemoattractant protein 1/chemokine (C-C motif)
80 ing tumor necrosis factor alpha (TNF-alpha); monocyte chemoattractant protein 1; macrophage inflammat
81 ce was observed, certain chemokines (RANTES, monocyte chemoattractant protein 1[MCP-1], and IP-10) we
82 ntercellular adhesion molecule-1], and MCP1 [monocyte chemoattractant protein 1]), increases inflamma
83 10]), and proinflammatory cytokines (MCP-1 [monocyte chemoattractant protein 1], MIP-1alpha/beta [ma
84 we show that TXA(2) mimetic, I-BOP, induced monocyte chemoattractant protein -1(MCP-1)/chemokine (C-
85 ion correlated with decreased levels of MCP (monocyte chemoattractant protein)-1 and IL (interleukin)
86 or necrosis factor-alpha (-16% versus +12%), monocyte chemoattractant protein-1 (-13% versus +0.2%),
87 ations of inflammatory biomarkers, including monocyte chemoattractant protein-1 (adjusted OR 9.0 [95%
88 mL; low-BCAA: 5.7 +/- 1 pg/mL; P = 0.01) and monocyte chemoattractant protein-1 (BCAA: -0.4% +/- 9%;
89 d PGE(2)-induced production of the chemokine monocyte chemoattractant protein-1 (CCL2), which was lin
90 an IC50 of 22.8 nM but was inactive against monocyte chemoattractant protein-1 (CCL2)-mediated calci
91 5), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.0
92 ion, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower
93 6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and C-reactiv
95 ited TNF-alpha-induced inflammatory factors, monocyte chemoattractant protein-1 (MCP-1) and interleuk
96 so increased levels of inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1) and MCP-1 ind
97 ble cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak inte
98 h as interleukin (IL)-6, IL-1beta, IL-8, and monocyte chemoattractant protein-1 (MCP-1) and the secre
99 d and is accompanied by increases in mRNA of monocyte chemoattractant protein-1 (MCP-1) and tumor nec
100 VSMC stimulated by TGF-beta/AdSmad3 revealed monocyte chemoattractant protein-1 (MCP-1) as a likely f
101 pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL
102 lls, which directly stimulates expression of monocyte chemoattractant protein-1 (Mcp-1) by macrophage
103 an obligate dimeric mutant of the chemokine monocyte chemoattractant protein-1 (MCP-1) by substituti
105 uced Src and STAT3 tyrosine phosphorylation, monocyte chemoattractant protein-1 (MCP-1) expression an
106 JNK as the exclusive mediator of FFA-induced monocyte chemoattractant protein-1 (MCP-1) expression in
109 a murine model of an arteriovenous fistula, monocyte chemoattractant protein-1 (MCP-1) mRNA and prot
110 chemokine receptor 2 (CCR2) with its ligand, monocyte chemoattractant protein-1 (MCP-1) promotes canc
114 mobility mass spectrometry (IMMS) to analyze monocyte chemoattractant protein-1 (MCP-1), a CC chemoki
116 -1beta (IL-1beta), the cytokines IL-8, IL-6, monocyte chemoattractant protein-1 (MCP-1), and growth-r
117 yperactivation of ERK and p38 in response to monocyte chemoattractant protein-1 (MCP-1), and increase
118 phage accumulation, diminished expression of monocyte chemoattractant protein-1 (MCP-1), and lower le
119 activation-regulated chemokine (TARC), IL-8, monocyte chemoattractant protein-1 (MCP-1), and murine b
120 Stroke outcome, expression of brain CD36, monocyte chemoattractant protein-1 (MCP-1), CCR2, and pl
122 n (IFN)-gamma- inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), IFN-gamma, i
124 We have previously shown that the chemokine, monocyte chemoattractant protein-1 (MCP-1), is a mediato
125 n-gamma-inducible protein of 10 kDa (IP-10), monocyte chemoattractant protein-1 (MCP-1), tumor necros
126 netic basis of circulating concentrations of monocyte chemoattractant protein-1 (MCP-1), we conducted
131 that interact with the oligomeric chemokine Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 with dif
132 rated increased expression of iNOS, C1r, and monocyte chemoattractant protein-1 (MCP-1); MCP-1 expres
133 RK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as
134 to chronic pain includes the upregulation of monocyte chemoattractant protein-1 (MCP-1/CCL2) and its
135 proinflammatory cytokine IL-6 and chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) in respo
136 keratinocytes up-regulated the expression of monocyte chemoattractant protein-1 (MCP-1/CCL2), TNFalph
138 ic pain, and mice overexpressing its ligand, monocyte chemoattractant protein-1 (MCP1; also known as
139 ange messenger RNA: interleukin-1beta = 7.6, monocyte chemoattractant protein-1 = 15.3, and tumor nec
140 ls of IL-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 after stimulation wit
141 n the vascular wall (decreased production of monocyte chemoattractant protein-1 and activation of p38
143 ukin-6, tumor necrosis factor) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines
144 plasia and pro-inflammatory gene expression (monocyte chemoattractant protein-1 and cytokine-induced
145 or necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1 and decreased M2 mark
146 ry and proproliferative mediators, including monocyte chemoattractant protein-1 and hypoxia-inducible
147 Seeded BMCs secreted significant amounts of monocyte chemoattractant protein-1 and increased early m
148 d at the promoters of the inflammatory genes monocyte chemoattractant protein-1 and interleukin-6 in
149 in significantly reduced production of serum monocyte chemoattractant protein-1 and interleukin-6 lev
150 sumption by inflammatory monocytes and serum monocyte chemoattractant protein-1 and interleukin-6 wer
151 -infected MSKO mouse livers had: (1) greater monocyte chemoattractant protein-1 and macrophage inflam
153 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 and reduced mRNA and
154 25(OH)(2)D(3) supplementation also inhibited monocyte chemoattractant protein-1 and stimulated adipon
155 macrophages showed reduced migration toward monocyte chemoattractant protein-1 and transmigration th
156 uction of key proatherogenic factors such as monocyte chemoattractant protein-1 and tumor necrosis fa
158 oliferating cell nuclear antigen+ cells, and monocyte chemoattractant protein-1 and vascular cell adh
159 okine (C-C motif) ligand 5 and expression of monocyte chemoattractant protein-1 and vascular cell adh
160 sAPPbeta) and two neuroinflammatory markers (monocyte chemoattractant protein-1 and YKL-40) were meas
161 ficantly with matrix metalloproteinase-3 and monocyte chemoattractant protein-1 at baseline, biomarke
162 iR-132 and demonstrated that miR-132 induces monocyte chemoattractant protein-1 at least in part via
163 7/BL6 mice, markedly augmented the levels of monocyte chemoattractant protein-1 bound to RBCs, which
164 osis factor-alpha, IL-1beta, IL-6, IL-8, and monocyte chemoattractant protein-1 by co-cultured dendri
165 ts contained increased leptin, resistin, and monocyte chemoattractant protein-1 compared with plasma
167 nside-out activation of beta(2) integrins by monocyte chemoattractant protein-1 did not change IL-13-
168 y reduced hepatic inflammation, particularly monocyte chemoattractant protein-1 expression and macrop
169 ell as vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression in endothe
170 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 expression induced by
176 eased plasma tumor necrosis factor-alpha and monocyte chemoattractant protein-1 levels in Tg-hCBS apo
177 igation and puncture, and interleukin 10 and monocyte chemoattractant protein-1 levels were higher in
179 essed and secreted, T-cell activation-3, and monocyte chemoattractant protein-1 mRNAs were lower comp
181 Pio also did not attenuate Ang II-induced monocyte chemoattractant protein-1 production in PPARgam
182 responses to TLR2 and TLR4 ligands, reduced monocyte chemoattractant protein-1 production, and preve
183 ammation, limits neutrophils recruitment and monocyte chemoattractant protein-1 production, thus redu
185 cts of Klotho signaling on interleukin-8 and monocyte chemoattractant protein-1 promoter recruitment
186 Given its unique role, future studies into monocyte chemoattractant protein-1's exact role during s
187 he TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, an
188 ed with increased renal expression of MCP-1 (monocyte chemoattractant protein-1) and VLA-4 (very-late
189 elian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis a
190 ray indicated that the chemokine CCL2/MCP-1 (monocyte chemoattractant protein-1) was strongly induced
191 remote myocardium (e.g., 12-fold increase of monocyte chemoattractant protein-1), although levels wer
192 CI and other wild type CC chemokines, MCP-1 (monocyte chemoattractant protein-1), MIP-1beta, and RANT
194 m levels of CD40 ligand, serum amyloid A and monocyte chemoattractant protein-1, (b) limited evidence
195 5%, P < 0.002; interleukin-6, 13%, P < 0.01; monocyte chemoattractant protein-1, 10%, P < 0.0006) and
196 increased CD68, tumor necrosis factor alpha, monocyte chemoattractant protein-1, alpha-smooth muscle
197 ated lipocalin, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and fractional hypox
198 with statistically different levels of IL-6, monocyte chemoattractant protein-1, and heat-shock prote
199 ed secretion of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and interleukin-12.
200 lecule-1, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and interleukin-17A;
201 increased expression of inflammatory genes, monocyte chemoattractant protein-1, and interleukin-6, a
202 irculating levels of P-selectin, E-selectin, monocyte chemoattractant protein-1, and macrophage conte
203 atory cytokines tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and macrophage infla
204 lating factor, keratinocyte chemoattractant, monocyte chemoattractant protein-1, and macrophage infla
205 ative stress, expression of endothelin-1 and monocyte chemoattractant protein-1, and monocyte homing.
206 roinflammatory cytokines (interleukin-1beta, monocyte chemoattractant protein-1, and tumor necrosis f
207 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f
208 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f
209 L-8, IL-10, interferon-inducible protein-10, monocyte chemoattractant protein-1, and tumor necrosis f
210 ession of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and vascular endothe
211 IL-8, granulocyte colony-stimulating factor, monocyte chemoattractant protein-1, C-reactive protein,
212 growth factor, hepatocyte growth factor and monocyte chemoattractant protein-1, contributing to deve
213 ased mRNA and immunostaining of IL-1beta and monocyte chemoattractant protein-1, decreased mRNA of in
214 proinflammatory mediators interleukin-6 and monocyte chemoattractant protein-1, fibroblast growth fa
215 binding oligomerization domain containing-2, monocyte chemoattractant protein-1, IL-2, and IL-12p40 i
216 micked by stimulation of Hmox1(+/+) SCs with monocyte chemoattractant protein-1, IL-6, IL-1beta, and
217 tate dehydrogenase, as well as expression of monocyte chemoattractant protein-1, IL-6, IL-1beta, and
219 inflammatory response through alteration of monocyte chemoattractant protein-1, interleukin-1beta, a
220 of cytokines keratinocyte-derived chemokine, monocyte chemoattractant protein-1, interleukin-6 (IL-6)
221 m TK-/- mice exhibited blunted production of monocyte chemoattractant protein-1, interleukin-6, and m
222 oduction of cytokines and chemokines, namely monocyte chemoattractant protein-1, interleukin-6, and m
223 icantly higher levels of expression of cKIT, monocyte chemoattractant protein-1, interleukin-6, strom
224 ion, as denoted by the reduced expression of monocyte chemoattractant protein-1, intracellular adhesi
225 cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1, is markedly increase
226 ial protein expression of interleukin-18 and monocyte chemoattractant protein-1, key mediators of car
227 ngII-induced expression of cyclooxygenase-2, monocyte chemoattractant protein-1, macrophage inflammat
228 protein-1alpha, and C-reactive protein, and monocyte chemoattractant protein-1, macrophage inflammat
230 terferon-gamma inducible protein-10 [IP-10], monocyte chemoattractant protein-1, macrophage inflammat
231 heal had higher tumor necrosis factor-alpha, monocyte chemoattractant protein-1, matrix metallopeptid
232 proteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant protein-1, P-selectin, fibrinog
233 ric inhibitory polypeptide, insulin, leptin, monocyte chemoattractant protein-1, pancreatic polypepti
234 Expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, plasminogen activato
235 e (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, plays a critical rol
236 sis included higher levels of interleukin-8, monocyte chemoattractant protein-1, resistin, soluble in
237 sociated phospholipase A2 mass and activity, monocyte chemoattractant protein-1, soluble endothelial
238 methylarginine, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, soluble vascular cel
239 reduced astrogliosis, interleukin-1beta, and monocyte chemoattractant protein-1, suggesting a paracri
240 yed similar up-regulation of miR-132/212 and monocyte chemoattractant protein-1, supporting in vivo r
241 in systolic BP, heart rate variability, and monocyte chemoattractant protein-1, together with reduce
242 mug/mL significantly decreased production of monocyte chemoattractant protein-1, tumor necrosis facto
243 nes for interleukin (IL)-1beta, IL-6, IL-10, monocyte chemoattractant protein-1, tumor necrosis facto
244 , intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1, were also determined
245 idenced by the upregulation of ephrin B2 and monocyte chemoattractant protein-1, which are 2 stretch-
246 oprotein 1 stimulates macrophages to secrete monocyte chemoattractant protein-1, which then activates
247 nd decreased production of oxidant-inducible monocyte chemoattractant protein-1, which we have previo
249 toreceptor cultures exposed to starvation or monocyte chemoattractant protein-1-stimulated (MCP-1-sti
261 crosis factor-alpha) and chemokines (such as monocyte chemoattractant protein-1/ chemokine (C-C motif
262 Importantly, our data demonstrate that the monocyte chemoattractant protein-1/C-C chemokine recepto
263 n stimulation with CXCL16 astrocytes release monocyte chemoattractant protein-1/CCL2 and (2) the neur
265 leukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 in
266 8/C-X-C motif chemokine ligand 8 P=0.04, and monocyte chemoattractant protein-1/chemokine ligand 2 P=
267 e ASK1-p38 pathway induced expression of the monocyte chemoattractant protein 3 (MCP-3) gene, which p
268 the cognate chemokine ligand CCL7 (formerly monocyte chemoattractant protein-3 (MCP-3)) using chimer
269 ding T(H)2 (IL4 receptor [IL4R], IL13, CCL13/monocyte chemoattractant protein 4, CCL17/thymus and act
272 t mechanism that results in release of MCPs (monocyte chemoattractant proteins) and monocyte mobiliza
273 vels of inflammatory factors IL-1beta, IL-6, monocyte chemoattractant protein, and macrophage inflamm
275 ry cytokines, matrix metalloproteinases, and monocyte chemoattractant protein from murine RPE cells.
276 s, Syk signaling increased the expression of monocyte chemoattractant protein MCP-1, which in periphe
277 such as tumor necrosis factor (TNF) -alpha, monocyte chemoattractant protein (MCP) -1, and intercell
280 sites of microbial infection in response to monocyte chemoattractant protein (MCP)-1 (CCL2) secretio
281 ession of interleukin (IL)-6 (P = 0.010) and monocyte chemoattractant protein (MCP)-1 (P = 0.04) in u
282 hage-colony-stimulating factor (GM-CSF), and monocyte chemoattractant protein (MCP)-1 and also invasi
283 onor PAR-1 is required to generate the local monocyte chemoattractant protein (MCP)-1 needed to recru
284 L-13 showed strong correlations with AHR and monocyte chemoattractant protein (MCP)-1 with asthma sev
285 -E8 colocalizes with both angiotensin II and monocyte chemoattractant protein (MCP)-1 within vascular
286 tion by adipocytes of serum amyloid A (SAA), monocyte chemoattractant protein (MCP)-1, and hyaluronan
287 protein levels of interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1, and osteoprote
289 nflammatory protein (MIP)-1alpha, MIP-1beta, monocyte chemoattractant protein (MCP)-1, interferon gam
290 mokines, including IL-17A, IL17F, IFN-gamma, monocyte chemoattractant protein (MCP)-1, MCP-2, and int
291 vestigate the role of CCR2, the receptor for monocyte chemoattractant protein (MCP)-1, MCP-2, and MCP
292 on of IFN-gamma, IL-1RA, IL-6, IL-10, IL-19, monocyte chemoattractant protein (MCP)-1, MCP-2, MCP-3,
293 urpose of this study was to evaluate whether monocyte chemoattractant protein (MCP)-1-activated monoc
295 igomerization propensities of the chemokines monocyte chemoattractant protein (MCP)-1/CCL2 and MCP-3/
297 D163), interleukin 6 (IL-6), interleukin 18, monocyte chemoattractant protein (MCP-1), autotaxin (ATX
298 origin for CFPs, we investigated the role of monocyte chemoattractant protein (MCP1) in mediating CFP
299 and induced a significantly higher degree of monocyte chemoattractant protein production by JR-CSF/hu